Medical isotope developer IsoRay Medical said that MD Anderson Cancer Center at the University of Texas has begun ordering its cesium-131 brachytherapy seeds.
MD Anderson will use the seeds as part of its continuing clinical study investigating brachytherapy's ability to help control intermediate-risk prostate cancer, according to IsoRay.
The current phase of the study will compare cesium-131 to other, previously used isotopes, IsoRay said. Principal investigator Dr. Steven Frank aims to evaluate cesium-131's effectiveness in treating intermediate-risk prostate cancer and its benefits for patient quality of life. The study will also evaluate prostate-specific antigen (PSA) response and patients' return to urinary function baseline and normal lifestyle activities, according to the firm.
